Egalet Corp. Company Profile (NASDAQ:EGLT)

Analyst Ratings

Consensus Ratings for Egalet Corp. (NASDAQ:EGLT) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $18.00 (166.67% upside)

Analysts' Ratings History for Egalet Corp. (NASDAQ:EGLT)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Janney Montgomery ScottInitiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2015GuggenheimReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2015JMP SecuritiesBoost Price TargetOutperform$18.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2014Stifel NicolausLower Price TargetBuy$20.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Egalet Corp. (NASDAQ:EGLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q116($0.87)($0.76)$3.50 million$2.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.91)($0.28)$2.80 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.90)($0.81)$1.62 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.02)($0.98)$1.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.98)($1.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.69)($0.48)$5.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.77)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.42)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.16)($1.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Egalet Corp. (NASDAQ:EGLT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Egalet Corp. (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Egalet Corp. (NASDAQ:EGLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/6/2016Robert S RadieCEOSell15,000$5.01$75,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Robert S RadieCEOSell5,000$4.94$24,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Stan MusialCFOSell13,480$5.06$68,208.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Robert S RadieCEOSell5,000$5.07$25,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Stan MusialCFOSell10,000$5.06$50,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2016Jeffrey M DaynoInsiderSell536$4.65$2,492.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Deanne F MelloyInsiderSell860$6.96$5,985.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Robert S RadieCEOSell5,000$6.99$34,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Robert S RadieCEOSell10,000$6.97$69,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Robert S. RadieCEOSell10,000$9.65$96,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Robert S. RadieCEOSell5,000$10.52$52,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Deanne F MelloyInsiderSell860$11.42$9,821.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Robert S RadieCEOSell15,000$12.27$184,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Stan MusialCFOSell8,480$12.32$104,473.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Mark StrobeckInsiderSell5,220$12.56$65,563.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Robert S RadieCEOSell6,000$11.97$71,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Robert S RadieCEOSell9,000$12.53$112,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Mark StrobeckInsiderSell10,440$12.98$135,511.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Stan MusialCFOSell8,480$13.20$111,936.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Robert S RadieCEOSell11,130$11.25$125,212.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015Jeffrey M DaynoInsiderSell2,500$8.87$22,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Mark StrobeckInsiderSell3,480$5.09$17,713.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Robert S RadieCEOSell11,130$5.11$56,874.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Robert S RadieCEOSell40,040$9.61$384,784.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Robert S RadieCEOSell49,000$9.74$477,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Mark StrobeckInsiderSell5,135$9.20$47,242.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Mark StrobeckInsiderSell5,700$10.28$58,596.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Mark StrobeckInsiderSell3,085$11.50$35,477.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Stan MusialCFOSell13,920$11.05$153,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Jean Francois FormelaDirectorBuy41,667$12.00$500,004.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Life Science Ventures SunstoneMajor ShareholderBuy133,333$12.00$1,599,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Egalet Corp. (NASDAQ:EGLT)
DateHeadline
07/22/16 06:58 AMIncreased Stock Volatility Watch: Egalet Corporation (NASDAQ:EGLT) - Engelwood Daily
07/21/16 07:17 AMEgalet Corporation (EGLT) Jumps 7.59% on July 20 - Equities.com
07/21/16 05:00 AMEgalet to Host Conference Call and Webcast on August 4, 2016 to Discuss Second Quarter 2016 Financial Results - [PR Newswire] - WAYNE, Pa., July 21, 2016 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing ...
07/19/16 05:01 AM6:01 am Egalet announces the issuance of two patents by the USPTO for its Guardian Technology -
07/19/16 05:00 AMEgalet Announces Issuance of Two New U.S. Patents for Guardian™ Technology - [PR Newswire] - WAYNE, Pa., July 19, 2016 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the issuance of two patents by the U.S. Patent and Trademark Office (USPTO) for Egalet's proprietary Guardian™ Technology. U.S. patent number 9,358,295 covers through 2031 immediate-release formulations intended to be resistant to abuse by intake of alcohol, and U.S. patent number 9,375,428 covers through 2024 extended-release formulations of opioids. "The newly issued patents further strengthen our ability to grow our business with immediate- and extended-release formulations of products using Guardian Technology," said Bob Radie, president and chief executive officer of Egalet.
07/14/16 03:26 PMEgalet Corporation (NASDAQ:EGLT) Sellers Covered 2.67% of Their Shorts - Consumer Eagle
07/13/16 03:59 PMActive Stocks to Watch: Egalet Corporation (NASDAQ:EGLT), Synchrony Financial (NYSE:SYF), Pfizer Inc. (NYSE:PFE ... - KC Register
07/09/16 07:16 AMIncreased Volatility on Shares of: Egalet Corporation (NASDAQ:EGLT) - Engelwood Daily
07/09/16 07:16 AMEgalet Corporation (EGLT) Jumps 5.5% on July 08 - Equities.com
07/07/16 06:55 AMChief Financial Officer of Egalet Corporation (NASDAQ:EGLT), Musial Stan, sells 10,000 shares worth $50,600
07/07/16 05:11 AMEgalet to Present at Cantor Fitzgerald Healthcare Conference - [at noodls] - WAYNE, Penn., July 7, 2016/PRNewswire / -- Egalet Corporation (Nasdaq: EGLT) ('Egalet'), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative ...
07/06/16 09:37 PMBroker Outlook For Egalet Corp (EGLT) - Fiscal Standard
07/06/16 08:31 AMChief Business Officer of Egalet Corporation (NASDAQ:EGLT), Strobeck Mark, sells 8,700 shares worth $40,716
07/05/16 11:52 AMETF’s with exposure to Egalet Corp. : July 5, 2016 -
07/04/16 03:31 PMBroker Outlook For The Week Ahead Egalet Corp (EGLT) - Fiscal Standard
06/30/16 09:13 PMCheck on Share Volatility: Egalet Corporation (NASDAQ:EGLT) - Engelwood Daily
06/30/16 04:01 PMEgalet Corporation (NASDAQ:EGLT) Shorted Shares Decreased By 2.67% - Engelwood Daily
06/28/16 12:31 PMEgalet Reveals FDA Advisory Committee Meeting For ARYMO ER Extended-Release Tablets - Egalet Corporation (NASDAQ: EGLT) revealed Tuesday that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA has been convened for August 4. The meeting would review the new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate. Egalet ...Full story available on Benzinga.com
06/28/16 08:11 AMEgalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 for Lead Abuse-Deterrent Candidate ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets - [PR Newswire] - WAYNE, Pa., June 28, 2016 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for August 4, 2016, to review the new drug application (NDA) for ARYMO™ ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate. ARYMO ER was developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
06/26/16 03:24 PMEgalet Corporation (EGLT) is Trading Higher on Unusual Volume for June 23 - Equities.com
06/26/16 03:24 PMEgalet Corporation (EGLT) Jumps 10.65% on June 23 - Equities.com
06/24/16 10:34 AMShare Volatility Check for: Egalet Corporation (NASDAQ:EGLT) - Press Telegraph
06/23/16 06:43 AMEgalet Corporation (EGLT) Hits New 52-week Low During June 21 Session - Equities.com
06/23/16 06:43 AMEgalet Corporation (EGLT) Jumps 9.03% on June 22 - Equities.com
06/22/16 03:53 PMEgalet Corporation (NasdaqGM:EGLT) Stock Momentum Hits EXTREME Weakness - CML News
06/21/16 03:49 PMEGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/17/16 03:37 PMEgalet Corporation (EGLT) Hits New 52-week Low During June 14 Session - Equities.com
06/17/16 07:46 AMEgalet Corp (EGLT) Current Analyst Ratings - Fiscal Standard
06/17/16 07:46 AMEgalet Corporation (EGLT) Hits New 52-week Low During June 15 Session - Equities.com
06/16/16 03:52 PMEGALET CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/13/16 03:29 PMData Presented at College on Problems of Drug Dependence (CPDD) Meeting Show Egalet's Guardian Technology Offers Both Strong Abuse-Deterrent Features and Precision Drug Delivery - [at noodls] - WAYNE, Pa., June 13, 2016/PRNewswire / -- Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain ...
06/10/16 05:09 AMEgalet President and CEO Bob Radie Named EY Entrepreneur of the Year® - [at noodls] - WAYNE, Penn., June 10, 2016/PRNewswire / -- Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain ...
06/07/16 09:27 PMEgalet Corporation (EGLT) Jumps 5.79% on June 06 - Equities.com
06/06/16 07:06 AMEgalet Corp (EGLT) Broker Price Targets For The Coming Week - Share Trading News
06/01/16 04:00 PMBuy, Sell Or Hold Rating For Egalet Corp (EGLT)? - Share Trading News - Buy, Sell Or Hold Rating For Egalet Corp (EGLT)?Share Trading NewsEgalet Corp has a 50 day moving average of 6.16 and a 200 day moving average of 7.86. The stock's market capitalization is 142.63M, it has a 52-week low of 4.96 and a 52-week high of 16.59. The share price of the company (EGLT) was up +1.96%, with a ...
06/01/16 08:14 AMEgalet Corp (EGLT) Jumps 6.59% on May 30 - Equities.com - Egalet Corp (EGLT) Jumps 6.59% on May 30Equities.comEgalet Corp (EGLT) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 6.59% to $5.66, representing a gain of $0.35 per share. Some 73,533 shares traded hands on 593 trades, compared with an average daily ...and more »
05/28/16 10:39 AMEgalet Corp (EGLT) Jumps 6.59% on May 27 - Equities.com - Egalet Corp (EGLT) Jumps 6.59% on May 27Equities.comEgalet Corp (EGLT) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 6.59% to $5.66, representing a gain of $0.35 per share. Some 73,533 shares traded hands on 593 trades, compared with an average daily volume ...and more »
05/26/16 10:47 AMEgalet Corp (EGLT) Updated Broker Price Targets - Share Trading News - Egalet Corp (EGLT) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Egalet Corp (EGLT). The latest reports which are currently in issue on Tuesday 24th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...Egalet Corporation (NASDAQ:EGLT) Shorts Decreased by 6.54% After Short CoveringWall Street Hints and Newsall 2 news articles »
05/23/16 08:10 AMEGALET CORP Files SEC form 8-K, Other Events -
05/23/16 05:06 AMEgalet Settles Patent Litigations with Purdue Pharma - [at noodls] - WAYNE, Pa., May 23, 2016/PRNewswire / -- Egalet Corporation (Nasdaq: EGLT) ('Egalet'), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative ...
05/20/16 10:46 AMETF’s with exposure to Egalet Corp. : May 20, 2016 -
05/19/16 12:04 PMEGALET CORP Financials -
05/17/16 01:35 PMEgalet Corp. :EGLT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/12/16 07:17 AMEgalet Human Abuse Potential Data at American Pain Society Annual Meeting Demonstrates Significantly Lower Intranasal Abuse Potential of ARYMO™ ER Compared to MS Contin® - [at noodls] - WAYNE, Pa., May 12, 2016/PRNewswire / -- Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain ...
05/10/16 09:35 AMEGALET CORP Files SEC form 10-Q, Quarterly Report -
05/10/16 06:07 AMQ1 2016 Egalet Corp Earnings Release - Before Market Open -
05/10/16 05:22 AMEgalet reports 1Q loss -
05/10/16 05:08 AMEgalet Reports First Quarter 2016 Financial Results - [at noodls] - WAYNE, Pa., May 10, 2016/PRNewswire / -- Egalet Corporation (Nasdaq: EGLT) ('Egalet'), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative ...
05/05/16 05:21 AMEgalet Announces Scientific Presentations at American Pain Society Meeting - [at noodls] - WAYNE, Pa., May 5, 2016/PRNewswire / -- Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and ...
03/08/16 05:20 AMEgalet reports 4Q loss -

Social

About Egalet Corp.

Egalet Corp. logoEgalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGLT
  • CUSIP:
Key Metrics:
  • Previous Close: $6.75
  • 50 Day Moving Average: $5.41
  • 200 Day Moving Average: $6.75
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $165.08M
  • Beta: -0.27
  • Current Year EPS Consensus Estimate: $-3.23 EPS
  • Next Year EPS Consensus Estimate: $-1.97 EPS
Additional Links:
Egalet Corp. (NASDAQ:EGLT) Chart for Saturday, July, 23, 2016